Gilead Sciences, Inc. $GILD Holdings Decreased by Vise Technologies Inc.

Vise Technologies Inc. cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 99,238 shares of the biopharmaceutical company’s stock after selling 20,862 shares during the period. Vise Technologies Inc.’s holdings in Gilead Sciences were worth $14,791,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Investment Partners LTD. grew its holdings in shares of Gilead Sciences by 5.4% in the 3rd quarter. Investment Partners LTD. now owns 4,084 shares of the biopharmaceutical company’s stock worth $609,000 after acquiring an additional 211 shares during the last quarter. Blue Fin Capital Inc. purchased a new stake in shares of Gilead Sciences during the third quarter valued at $201,000. Summit Global Investments lifted its holdings in shares of Gilead Sciences by 41.3% during the third quarter. Summit Global Investments now owns 16,549 shares of the biopharmaceutical company’s stock valued at $2,467,000 after purchasing an additional 4,837 shares during the last quarter. MGO One Seven LLC boosted its position in shares of Gilead Sciences by 31.0% in the 3rd quarter. MGO One Seven LLC now owns 17,858 shares of the biopharmaceutical company’s stock valued at $2,662,000 after purchasing an additional 4,231 shares during the period. Finally, Americana Partners LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $369,000. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of analyst reports. Bank of America lifted their price target on Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research note on Tuesday, October 20th. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Cantor Fitzgerald lifted their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday. Truist Financial boosted their price target on shares of Gilead Sciences from $158.00 to $181.00 and gave the company a “buy” rating in a report on Friday. Finally, BMO Capital Markets restated an “outperform” rating and issued a $184.00 price target on shares of Gilead Sciences in a research report on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $169.19.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Several analysts raised their price targets for Gilead, setting targets of $175, $181, $183, $188, $190, and $200, while another raised its target to $131. The cluster of increases suggests improving confidence in Gilead’s earnings outlook and valuation. Gilead price target raised to $190 Gilead price target raised to $175 Gilead price target raised to $131 Gilead price target raised to $188 Gilead price target raised to $200 Gilead price target raised to $183 Gilead price target raised to $181
• Positive Sentiment: Morgan Stanley reiterated a Buy view on Gilead, adding to the positive analyst sentiment and supporting the case that the company’s HIV franchise and broader pipeline can sustain growth. Gilead receives a Buy from Morgan Stanley
• Positive Sentiment: Recent coverage points to strong HIV drug sales as a key reason GILD reached new highs. A separate investment article also highlighted Gilead as an attractive dividend-paying biotech, reinforcing its appeal to income-focused investors. Why GILD surged to 52-week highs Dividend-paying biotech stock article
• Neutral Sentiment: Gilead plans to present at upcoming fourth-quarter investor conferences, potentially giving management an opportunity to provide updates on its pipeline, commercial performance, and guidance. Gilead investor conference presentations
• Neutral Sentiment: A peer comparison and a separate analyst rating update provide additional valuation context, but the available headlines do not specify enough detail to determine a direct effect on GILD. Gilead and rivals comparison Gilead analyst rating update
• Negative Sentiment: Gilead’s third-quarter outlook contains a cautionary element: revenue guidance was raised, but the EPS outlook worsened. That contradiction may limit gains if investors focus on margins, expenses, or earnings quality despite the strength of the HIV business. Gilead third-quarter earnings analysis

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. The trade was a 1.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director directly owned 12,894 shares in the company, valued at $1,916,306.28. The trade was a 58.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 96,000 shares of company stock worth $13,923,210. 0.30% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $170.68 on Monday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.32 and a quick ratio of 0.95. The company has a market capitalization of $211.63 billion, a price-to-earnings ratio of -54.01 and a beta of 0.35. Gilead Sciences, Inc. has a one year low of $114.02 and a one year high of $175.65. The company’s fifty day moving average price is $150.87 and its two-hundred day moving average price is $139.79.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter last year, the company posted $2.47 earnings per share. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. On average, analysts forecast that Gilead Sciences, Inc. will post -1.03 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. Gilead Sciences’s payout ratio is -103.80%.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.